Daiichi Sankyo

Daiichi Sankyo DSKYF Stock

$17.72   0.000000%
Add to favorites
Market Cap
$32.29B
LOW - HIGH [24H]
$17.45 - $17.45
VOLUME [24H]
$773.00
P/E Ratio
18.26
Earnings per share
$0.97
ISIN
JP3475350009
Price   Prediction

Daiichi Sankyo Price Chart

Sorry, that's all we've gotfor now...

Daiichi Sankyo (DSKYF) stock price today is 17.72 USD on OTC Markets OTCPK (0% on the day). Updated .

Daiichi Sankyo DSKYF Financial and Trading Overview

Daiichi Sankyo stock price 17.72 USD
Previous Close 17.72 USD
Open 17.45 USD
Bid 17.43 USD x 30000
Ask 17.97 USD x 10000
Day's Range 17.45 - 17.45 USD
52 Week Range 13.85 - 25.75 USD
Volume 773 USD
Avg. Volume 4.66K USD
Market Cap 32.29B USD
Beta (5Y Monthly) -0.106
PE Ratio (TTM) 18.26804
EPS (TTM) 0.97 USD
Forward Dividend & Yield 0.63 (3.54%)
Ex-Dividend Date March 30, 2027
1y Target Est N/A

DSKYF Valuation Measures

Enterprise Value -125758332928 USD
Trailing P/E 18.26804
Forward P/E 18.652632
PEG Ratio (5 yr expected) 2.06
Price/Sales (ttm) 0.013947323
Price/Book (mrq) 2.9053364
Enterprise Value/Revenue -0.054
Enterprise Value/EBITDA -0.335

Trading Information

Daiichi Sankyo Stock Price History

Beta (5Y Monthly) -0.106
52-Week Change -18.90%
S&P500 52-Week Change 12.07%
52 Week High 25.75 USD
52 Week Low 13.85 USD
50-Day Moving Average 17.69 USD
200-Day Moving Average 17.43 USD

DSKYF Share Statistics

Avg. Volume (3 month) 4.66K USD
Avg. Daily Volume (10-Days) 4.77K USD
Shares Outstanding 1.82B
Float 1.82B
Short Ratio N/A
% Held by Insiders 0.17%
% Held by Institutions 57.99%
Shares Short N/A
Short % of Float N/A
Short % of Shares Outstanding N/A

Dividends & Splits

Trailing Annual Dividend Rate 89
Trailing Annual Dividend Yield 502.25%
5 Year Average Dividend Yield 100.00%
Payout Ratio 0.5815
Last Split Factor 3:1

Financial Highlights

Fiscal Year

Fiscal Year Ends March 31, 2026
Most Recent Quarter (mrq) September 30, 2026
Next Fiscal Year End March 31, 2027

Profitability

Profit Margin 12.97%
Operating Margin (ttm) 12.57%
Gross Margin 71.20%
EBITDA Margin 16.20%

Management Effectiveness

Return on Assets (ttm) 4.64%
Return on Equity (ttm) 17.59%

Income Statement

Revenue (ttm) 2.31T USD
Revenue Per Share (ttm) 1262.4 USD
Quarterly Revenue Growth (yoy) 18.30%
Gross Profit (ttm) 1.65T USD
EBITDA 375.22B USD
Net Income Avi to Common (ttm) 300.45B USD
Diluted EPS (ttm) 0.97
Quarterly Earnings Growth (yoy) 82.89%

Balance Sheet

Total Cash (mrq) 680.84B USD
Total Cash Per Share (mrq) 373.65 USD
Total Debt (mrq) 500.33B USD
Total Debt/Equity (mrq) 28.11 USD
Current Ratio (mrq) 2.807
Book Value Per Share (mrq) 6.0991216

Cash Flow Statement

Operating Cash Flow (ttm) 156.7B USD
Levered Free Cash Flow (ttm) -165692882944 USD

Profile of Daiichi Sankyo

Country United States
State N/A
City Chuo
Address Daiichi Sankyo Building A/B
ZIP 103-8426
Phone 81 3 6225 1111
Website https://www.daiichisankyo.com
Industry Drug Manufacturers - General
Sector(s) Healthcare
Full Time Employees 20171

Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan and internationally. The company offers Enhertu for the treatment of HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule for colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3, as well as symptomatic TGCT; Vanflyta, a FLT3 inhibitor for the treatment of acute myeloid leukemia; Injectafer, a ferric carboxymaltose injection for the treatment of iron deficiency; and Datroway for the treatment of HR positive and HER2 negative breast cancer, as well as NSCLC. It also provides Lixiana and Savaysa, which are direct factor Xa inhibitors; Minnebro, Olmetec, Olmetec Plus, Rezaltas, Sevikar, and Sevikar HCT, which are antihypertensive agents; Nilemdo that lowers cholesterol; Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe that reduces cholesterol; and Efient, an anti-platelet agent. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgality for the treatment of migraine attacks; Pralia for the treatment of osteoporosis and bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications and GCTB; Tarlige for the treatment of neuropathic pain; Venofer for the treatment of iron deficiency anemia; Vimpat, an anti-seizure medication; and Reyvow for the treatment of acute migraine attacks. Further, it provides Daichirona, a coronavirus RNA vaccine; Flumist, an intranasal live attenuated influenza vaccine; adsorbed cell culture-derived influenza vaccine; measles rubella combined vaccine; and mump vaccine. The company was formerly known as Sankyo Co. Ltd. and changed its name to Daiichi Sankyo Company, Limited in September 2005. Daiichi Sankyo Company, Limited was founded in 1899 and is headquartered in Chuo, Japan.

Q&A For Daiichi Sankyo Stock

What is a current DSKYF stock price?

Daiichi Sankyo DSKYF stock price today per share is 17.72 USD.

How to purchase Daiichi Sankyo stock?

You can buy DSKYF shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Daiichi Sankyo?

The stock symbol or ticker of Daiichi Sankyo is DSKYF.

Which industry does the Daiichi Sankyo company belong to?

The Daiichi Sankyo industry is Drug Manufacturers - General.

How many shares does Daiichi Sankyo have in circulation?

The max supply of Daiichi Sankyo shares is 1.82B.

What is Daiichi Sankyo Price to Earnings Ratio (PE Ratio)?

Daiichi Sankyo PE Ratio is 18.26804000 now.

What was Daiichi Sankyo earnings per share over the trailing 12 months (TTM)?

Daiichi Sankyo EPS is 0.97 USD over the trailing 12 months.

Which sector does the Daiichi Sankyo company belong to?

The Daiichi Sankyo sector is Healthcare.

$2.17T
Total marketcap
$70.38B
Total volume
BTC 58.16%   •   ETH 9.88%
Dominance
Select currency